
Two prescriptions that did not help do not automatically prove treatment resistance, and severe depression is not the same diagnosis as treatment-resistant depression. You will be able to identify what clinicians verify first, when ketamine enters the discussion, which alternatives may be more appropriate, and what monitored treatment involves.
Key takeaways
- Two adequate antidepressant trials usually establish treatment-resistant depression.
- Treat suicidal danger, psychosis, mania or medical emergencies before considering ketamine.
- Safety screening checks blood pressure, substance use, pregnancy, psychosis and medication risks.
- Esketamine uses a regulated nasal spray; intravenous ketamine requires supervised infusion monitoring.
What qualifies as treatment-resistant depression—and how is it different from severe depression?
Two adequate antidepressant trials without a clinically meaningful improvement are the usual threshold for treatment-resistant depression. An adequate antidepressant trial uses a therapeutic dose for enough time, with reasonable adherence; two prescriptions stopped after a few days or taken below the effective dose do not establish resistance.
1. Confirm major depressive disorder rather than another cause of low mood. Review the symptom pattern, duration, medical conditions, medications, substance use, and major psychosocial stressors.
2. Reconstruct each prior treatment. Record the drug, dose, duration, adherence, side effects, and degree of improvement. Check whether the trials were from different treatment attempts or medication classes.
3. Reassess bipolar-spectrum illness and psychotic symptoms. Bipolar depression needs a different treatment strategy, while active psychosis changes the risk assessment and treatment plan.
4. Optimise conventional care before considering ketamine or esketamine. Address missed doses, inadequate dosage, untreated substance use, medication interactions, and psychotherapy or other recommended treatments.
Severe depression describes the intensity and functional impact of symptoms, not whether treatment has failed. Someone can have severe depression without trying medication, while someone with treatment-resistant depression can have less severe current symptoms after several unsuccessful trials.
Persistent depressive disorder means depressed mood lasting at least two years in adults; it can coexist with major depressive episodes but is not itself a synonym for treatment resistance.
Suicidal thinking requires an immediate safety assessment, not an automatic ketamine referral. Catatonia, psychotic features, severe physical deterioration, or immediate life-threatening risk can make hospital care or electroconvulsive therapy more urgent, and ECT should not be postponed simply because ketamine is being considered.
When does ketamine become a reasonable option, and when is another treatment more urgent?
A psychiatrist considers ketamine therapy when major depressive disorder remains disabling after adequate treatment and a faster reduction in symptoms matters. That includes selected cases of ketamine for severe depression or suicidal depression, but ketamine is not a substitute for hospital care, continuous observation, a safety plan, or treatment of the illness driving the crisis.
| Option | Main role | When it takes priority |
|---|---|---|
| Medication optimisation | Correct dose, duration, adherence, interactions, and augmentation | Before ketamine when treatment has been incomplete or poorly tolerated |
| Psychotherapy | Addresses depressive patterns, stressors, and relapse risk | Alongside medication, or when psychological treatment is acceptable and safe |
| rTMS | Non-invasive treatment for depression without anaesthesia | When urgent physical risk is absent and repeated outpatient sessions are practical |
| Ketamine or esketamine | Rapid symptom reduction under clinical monitoring | After assessment when speed matters and no more urgent intervention is required |
| Electroconvulsive therapy (ECT) | Established acute treatment for severe depression | Catatonia, psychotic features, severe physical deterioration, or life-threatening risk |
| Emergency care | Protection, observation, and immediate treatment | Imminent suicide risk, inability to stay safe, or inability to eat, drink, or care for yourself |
Electroconvulsive therapy versus ketamine is not a simple choice between equivalent treatments. ECT should not be postponed merely because ketamine is under consideration when catatonia, psychosis, profound deterioration, or immediate danger is present. Even after ketamine helps, continue or optimise longer-term treatment and monitor for relapse, mania, psychosis, blood-pressure problems, cognitive effects, and problematic use.
What does a safety assessment check before ketamine treatment?
A ketamine therapy assessment starts with whether the expected benefit outweighs a short-term rise in blood pressure, heart rate, dissociation, sedation, or intracranial pressure. The clinician reviews your diagnosis, previous treatment response, physical health, current medicines, substance use, pregnancy status, and immediate safety.
The assessment checks:
- Blood pressure, cardiovascular disease, aneurysmal vascular disease, arteriovenous malformation, raised intracranial pressure, liver disease, and previous intracerebral haemorrhage. Uncontrolled hypertension and ketamine are an unsafe combination until blood pressure is stabilised.
- Bipolar disorder screening, psychotic symptoms, mania, cognitive impairment, and active substance-related instability. Bipolar depression or psychosis may require a different treatment plan.
- Medicines that increase sedation, blood pressure, or interaction risk, including benzodiazepines, opioids, stimulants, sedatives, and monoamine oxidase inhibitors. Do not stop a prescribed medicine without medical advice.
- Current or past ketamine misuse, alcohol or drug dependence, cravings, and access to unsupervised ketamine. A substance-use disorder does not automatically exclude treatment, but it demands tighter controls and monitoring.
- Pregnancy, plans to become pregnant, and breastfeeding. Treatment is usually delayed when risks to the fetus or infant cannot be assessed clearly.
- Suicidal thoughts, intent, access to means, past attempts, and ability to remain safe after the session. Immediate danger, severe self-neglect, catatonia, or psychotic depression may require hospital care or ECT rather than outpatient ketamine.
| Factor | What the clinician decides |
|---|---|
| Medical instability | Stabilise or defer treatment |
| Active psychosis or mania | Reassess diagnosis and treatment |
| High misuse risk | Add safeguards or consider alternatives |
| Immediate suicide risk | Arrange continuous emergency care |
Dr Milan Balakrishnan can use emergency, adult, or addiction psychiatry expertise to match the safety plan to these risks.
How do intravenous ketamine and intranasal esketamine differ during treatment?
The route changes who gives the medicine and how you leave. An intravenous ketamine infusion is prepared and administered by a clinician, usually over about 40 minutes. With intranasal esketamine, you use the prescribed nasal device yourself while a trained healthcare professional supervises each dose.
| Option | Who administers it | What ketamine treatment monitoring includes |
|---|---|---|
| Intravenous ketamine infusion | A clinician administers the infusion in a supervised setting | Blood pressure, pulse, oxygenation, mental status, dissociation, sedation, nausea, dizziness, and coordination during the infusion and recovery |
| Intranasal esketamine | You administer the nasal spray under direct healthcare-professional observation | Blood pressure and observation for dissociation, sedation, dizziness, nausea, impaired coordination, and judgment; monitoring continues for at least two hours |
Both routes can cause a temporary blood-pressure increase, altered perception, sleepiness, or poor coordination. The clinician delays discharge if symptoms have not settled or your blood pressure remains unsafe.
Arrange ketamine transport after treatment before the session begins. A responsible adult should take you home; do not drive, cycle in traffic, operate machinery, make important decisions, or use alcohol or sedatives afterward. After intranasal esketamine, avoid driving or machinery until the next day and until you have had a restful sleep.
Ask the clinic which adult supervision it requires at home, because you should not leave alone while judgment or coordination remains impaired.
What should you expect after a response, and how is longer-term care planned?
A single response often lasts days to weeks, so ketamine response duration varies considerably between patients. Repeated sessions or ketamine maintenance treatment can prolong improvement for some people, but long-term evidence is weaker than evidence for acute treatment, and no standard maintenance schedule matches ordinary antidepressant prescribing.
A longer-term plan usually considers:
- Continue or optimise an antidepressant, psychotherapy, or another evidence-based treatment that supports recovery.
- Consider further ketamine only when earlier benefit was clear, side effects were manageable, and the expected benefit outweighs risks.
- Choose an alternative such as medication augmentation, rTMS, or ECT when improvement is inadequate, relapse occurs quickly, or ketamine becomes unsuitable.
Ketamine does not remove the underlying vulnerability to depression or replace follow-up care. Clinicians use ketamine relapse monitoring to track mood, sleep, suicidal thoughts, functioning, blood pressure, cognitive changes, mania, psychosis, and treatment adherence. A written plan identifies who to contact and where to seek urgent help if symptoms return.
The review also includes ketamine misuse risks, including craving, unsupervised use, escalating doses, and use outside the treatment plan. Frequent requests for extra sessions, intoxication, or worsening substance-use problems can lead to treatment being paused and another approach being prioritised.
Benefits that fade quickly, troublesome adverse effects, or new bipolar or psychotic symptoms also prompt reassessment rather than automatic continuation.
Frequently asked questions
What qualifies as treatment-resistant depression?
Treatment-resistant depression usually means no clinically meaningful improvement after two adequate antidepressant trials. Each trial needs a therapeutic dose, enough treatment time and reasonable adherence.
Is treatment-resistant depression the same as severe depression?
No. Severity describes symptom intensity and functional impairment, while treatment resistance describes inadequate response to appropriate treatments. Depression can be severe without being treatment-resistant, or treatment-resistant without meeting the criteria for severe depression.
When is ketamine considered for depression?
Ketamine may be considered after an appropriate assessment confirms persistent depression despite adequate treatments and identifies a safe setting for administration. It is not a substitute for urgent care during psychosis, mania, intoxication, medical instability or immediate suicide risk.
What does a safety assessment check before ketamine treatment?
The assessment reviews suicidal risk, past mania or psychosis, blood pressure and cardiovascular history, substance use, pregnancy, current medicines, medical conditions and the support and monitoring available after treatment.
How do intravenous ketamine and intranasal esketamine differ?
Intravenous ketamine is delivered by infusion with continuous clinical monitoring. Intranasal esketamine is a regulated nasal spray administered under supervision, followed by an observation period; dosing schedules and access requirements differ.






